Skip to main content
Premium Trial:

Request an Annual Quote

Big Blue and the Genome

IBM is getting in on the $1,000 genome race — and plan to bring that cost even lower, to $100. The company's approach is based on what it calls "DNA transistor," reports the New York Times. (Our sister publication GenomeWeb Daily News covers this here.) IBM plans to develop a silicon-based system containing a million nanopores through which DNA can be ratcheted to sequence a genome in a few hours. "To bring about an era of personalized medicine, it isn't enough to know the DNA of an average person," says IBM's Gustavo Stolovitzky. "As a community, it became clear we need to make efforts to sequence in a way that is fast and cheap." However, Elaine Mardis tells the Times that previous attempts to develop a silicon-based nanopore system didn't pan out. "DNA strands seem to have a mind of their own," she says.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.